About
Contact & Profiles
Research Areas
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cardiovascular and exercise physiology
- Cardiovascular Function and Risk Factors
- Heart Failure Treatment and Management
- Gastrointestinal Tumor Research and Treatment
- Bone health and treatments
- Cardiac Health and Mental Health
- Viral-associated cancers and disorders
- Diabetes Treatment and Management
- Cardiac Imaging and Diagnostics
- Cardiac Structural Anomalies and Repair
University of Verona
2023-2024
International Mezzo Technologies (United States)
1995
10.1182/blood.2023023525
article
EN
Blood
2024-08-29
10.1378/chest.101.5.315s
article
EN
CHEST Journal
1992-05-01
10.1016/0895-7061(95)97729-b
article
EN
American Journal of Hypertension
1995-04-01
Introduction: Patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) have poor outcome. Time to first relapse progression (POD) has been consistently shown be an independent predictor of survival, patients experiencing early-POD, within 2 years since the diagnosis, representing a subgroup at greater risk death. On contrary, there is paucity large-scale treatment data on beyond (late-POD). Methods: In this international, observational cohort study, we evaluated outcomes amongst...
10.1002/hon.3164_348
article
EN
Hematological Oncology
2023-06-01
10.1016/0895-7061(95)97730-f
article
EN
American Journal of Hypertension
1995-04-01
Coming Soon ...